

Fig. 2 Comparison of mRNA expression of FOXP3 and CTLA4 in CD4+CD25^{high}+ T cells among the groups. The expression of FOXP3 (a) and CTLA4 (b) in separated CD4+CD25^{high}+ T cells were analysed by real-time reverse transcriptase-polymerase chain reaction as described in Materials and methods. Boxes represent lower and upper quartiles with the median value (solid line) between boxes, while the whiskers represent the minimum and maximum values. *, $P < 0.05$; #, $P < 0.01$; +, $P < 0.001$. For definitions of PNALT, CH and HS, see Fig. 1.

production stimulated with antigen-pulsed DC. We compared such responses between samples with or without CD4+CD25+ T cells. In PNALT patients, HCV NS5-specific T cell proliferation or IFN- γ production of CD25-depleted CD4+ T cells was significantly higher than those of the bulk CD4+ T cells (Fig. 3a,b). In contrast, in CH patients, such restoration did not occur significantly even when CD4+CD25+ T cells had been depleted (Fig. 3a,b). There was no difference in the production of IL-10 and TGF- β between bulk CD4+ T cells and CD25-depleted CD4+ T cells in both CH and PNALT patients (Fig. 3c,d). These results suggest that co-existing CD4+CD25+ T cells play an inhibitory role in the HCV-specific CD4+ T cell response, in which suppression was more potent in the PNALT than in the CH group.

CD127-FOXP3+ cells, regardless of their CD25 expression, are increased in patients with HCV infection

In the analyses of N-Treg, the frequency of CD4+CD25-FOXP3+ T cells in HCV-infected patients was higher than those in the healthy donors (Fig. 1d). These results suggest that CD4+FOXP3+ T cells, regardless of the degree of CD25




Fig. 3 Changes of hepatitis C virus (HCV)-specific CD4+ T cell responses with or without depletion of CD25+ T cells. Bulk CD4+ T cells or those depleted of CD25+ cells were cultured with autologous monocyte-derived dendritic cells in the presence of HCV-NS5 protein for 5 days as described in Materials and methods. (a) On day 4, [^3H]-thymidine was pulsed and the thymidine incorporation was counted with a β -counter. Before the pulsing, the culture supernatants were harvested and subjected to enzyme-linked immunosorbent assay for interferon- γ (b), interleukin-10 (c) and TGF- β (d), respectively. *, $P < 0.05$ by Mann-Whitney U -test. For definitions of PNALT and CH, see Fig. 1.




Fig. 4 Gating of CD4+CD127-FOXP3+ cells with variable CD25 expression under FACS analysis. After setting the gate on CD4+FOXP3+ cells [rectangle in the dot plot (a)], were displayed on the CD25 and CD127 axis (b). The presence of CD25+ (bold rectangle) and of CD25- cells (dotted rectangle) in CD4+FOXP3+ cells are shown in plot (b). The frequencies of these cells were analysed.


expression, increase in chronic HCV infection. Alternatively, it implies that higher expression of CD25 is not a universal marker for identifying FOXP3+ cells with regulatory activity. It has been reported that CD127 expression on CD4+ T cells is inversely correlated with FOXP3 expression, suggesting that CD127^{low}/negative cells consist of those with regulatory activity. In order to analyse regulatory T cell subsets more precisely, we first examined FOXP3 expression on CD127- or CD127+ cells paired with CD25 expression in patients with HCV infection (Fig. 4). As a result, the majority of CD4+FOXP3+ T cells belonged to the CD127- population irrespective of CD25 expression (Fig. 4). Next, we compared the frequency of CD4+CD127-FOXP3+ cells, which consist

of CD25+ and CD25- cells, among the subject groups (Fig. 5a). The frequency of CD4+CD127-FOXP3+ cells was similar in the CH and the PNALT groups, both of which were significantly higher than those in the HS (Fig. 5a). Finally, in order to estimate the profile of CD4+CD127-FOXP3+ cells according to CD25 expression, we compared the percentage of CD25+CD127-FOXP3+ or CD25-CD127-FOXP3+ cells in CD4+ T cells among the groups. The percentage of CD25+CD127-FOXP3+ T cells in CD4+ T cells was comparable for PNALT and CH (Fig. 5b). In clear contrast, the percentage of CD25-CD127-FOXP3+ T cells in the PNALT was lower than those in the CH (Fig. 5c). The frequencies of these cells were higher in the HCV-infected patients than in HS (Fig. 5b,c). When we set the focus on the proportion of CD25+CD127- or CD25-CD127- cells in the FOXP3+ cells in the periphery as a whole, we found that the proportion of CD25+CD127- cells in the PNALT was higher than that in the CH group (Fig. 5d). On the other hand, the proportion of CD25-CD127- cells in FOXP3+ cells was lower in the PNALT than in the CH group (Fig. 5e). Therefore, the phenotypic profiles of FOXP3+ T cells are distinct between PNALT and CH patients, with regard to the expression of CD127 and CD25.

DISCUSSION

Approximately 30–40% of chronically HCV-infected patients continue to display PNALT for decades. We previously reported the possible contribution of certain human leukocyte antigen haplotypes [23] or DC dysfunction in the maintenance of the PNALT state [24]. However, the precise mechanisms behind this important issue are yet to be

Fig. 5 Comparison in the frequencies of CD127- regulatory T cell subsets among the groups. Frequencies of CD127-FOXP3+ (a), CD127-CD25+FOXP3 (b) and CD127-CD25-FOXP3+ (c) cells among CD4+ T cells were determined by FACS analysis. The proportion of CD127-CD25+ (d) or CD127-CD25- (e) cells in CD4+FOXP3+ cells were also determined. Boxes represent lower and upper quartiles with the median value (solid line) between boxes, while the whiskers represent the minimum and maximum values. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.005$; ###, $P < 0.001$; +, $P < 0.0001$ by Mann-Whitney *U*-test. For definitions of PNALT, CH and HS, see Fig. 1.



established. Cumulative reports have shown that Th1/Tc1 type responses are instrumental in HCV-induced liver inflammation [7,25,26]. We thus hypothesized that some suppressor mechanisms exist in PNALT patients especially against HCV-specific Th1 and/or CTL reactions.

The involvement of Treg cells in the pathogenesis of various diseases has been reported [9–13]. Most of the studies presented the possibility that N-Treg play substantial roles in the induction of tolerance against aetiological self or nonself antigens, thus leading to alleviation or exacerbation of the disease severity. With regard to HCV infection, several groups have shown that N-Treg are increased both in the periphery and in the liver and are able to inhibit HCV-specific CD4+ or CD8+ T cell responses *in vitro* [17,18,27]. In this study, we showed that the frequency of N-Treg in HCV-infected patients is higher than those in the controls, which is consistent with the previous reports. However, the frequencies of N-Treg are indistinguishable between the patient groups with different disease activities. As for the functional aspect, the deprivation of CD4+CD25+ cells enhanced the HCV NS5-specific CD4+ T cell response in the PNALT than in the CH group, suggesting that co-existing Treg in the PNALT are more suppressive. In addition, the expression of FOXP3 and CTLA4, which are key molecules of the suppressor function, is higher in PNALT than in those with active hepatitis. Venken *et al.* [28] demonstrated that the degree of FOXP3 expression at the single-cell level of N-Treg is well correlated with their suppressive ability, which is supportive of our results. In contrast, Bolacchi *et al.* [29] reported that the frequency of TGF- β + N-Treg in the PNALT was higher than in the hepatitis group. Furthermore, their frequency was inversely correlated with the histological inflammatory grade, suggesting that TGF- β + Treg play active roles in alleviating hepatitis. The reasons for the lack of correlation between N-Treg and serum ALT or HCV RNA quantity in the present study may be because of the difference in the target of analyses, such as either peripheral or intra-hepatic Treg, or either TGF- β + or bulk Treg. Further analyses need to be performed on these important issues, as CD4+FOXP3+ Treg are reported to accumulate more in the portal tract of HCV-infected livers compared with those in the periphery [20].

During the observation period, about 30–40% of PNALT patients began to show elevated or fluctuating ALT abnormalities. What crucial factor triggers HCV-induced liver inflammation remains unknown. One of the plausible explanations is an antigenic shift accompanied by the occurrence of mutations in the HCV genome. In other words, hepatitis may flare up if the mutation raises HCV immunogenicity. Comprehensive analyses of HCV epitopes for CTL using overlapping peptides have shown that the HCV core and NS3 are more immunogenic than the remaining regions; however, the presence of an epitope hierarchy in Treg induction has been controversial. Li *et al.* [30] reported the possibility that Treg are expandable in response to

certain epitopes in HCV proteins. In two patients in whom we observed flare-up of hepatitis in this study, we were able to find that the expression of FOXP3 in N-Treg was high in the PNALT status, but declined in the active hepatitis stage (data not shown). Although it is difficult to state whether such phenotypic changes in N-Treg are the cause or the consequence of disease progression, these results suggest the involvement of N-Treg in the degree of HCV-mediated hepatitis. Further detailed study is needed to examine whether or not such changes in N-Treg are related to the sequence evolution in HCV genomes.

Recent research has disclosed that distinct types of Treg are present in humans. Currently, it is generally accepted that CD25+FOXP3+ is the most reliable marker for Treg, which is induced in parallel with the acquisition of suppressor ability. However, owing to the lack of phenotypic markers for specifically identifying adaptive Treg, their roles in clinical settings have been unclear. In this study, CD4+FOXP3+ cells increased in HCV-infected patients, who were either positive or negative for CD25. In contrast to thymus-derived N-Treg expressing a greater degree of CD25, adaptive Treg are presumed to be induced in the periphery with a lesser degree of CD25 expression. Thus, it is likely that CD4+CD25–FOXP3+ T cells in HCV infection contain some part of adaptive Treg.

Treg have been reported to express low levels of CD127 at their cell surface [31]. Furthermore, the expression of CD127 is inversely correlated with FOXP3 expression and with the suppressive function of CD25^{high}+ Treg. Liu *et al.* [22] pointed out the possibility that adaptive Treg are grouped into CD127– cells, which also include FOXP3–negative Tr1 or Th3 cells. Alternatively, You *et al.* [32] reported that murine CD4+CD25^{low}FOXP3+ T cells might be adaptive Treg, which exert a TGF- β -dependent suppressive function. Taking these reports into consideration, and in order to exclude activated CD25+ T cells, we examined CD4+CD127–CD25–FOXP3+ cells tentatively determined as part of adaptive Treg. In order to confirm that CD4+CD127– cells possess suppressive capacity, we co-cultured sorted CD4+CD127–CD25– or CD4+CD127–CD25+ cells with allogeneic CD4+ T cells stimulated with anti-CD3 and anti-CD28 antibodies. As a result, we found that CD4+CD127– cells, regardless of CD25 expression, significantly suppressed the proliferation of responder CD4+ T cells (manuscript in preparation). Of note is the finding that the frequency of CD127–CD25–FOXP3+ cells is higher in patients with active hepatitis than those in the PNALT group. One of the plausible explanations for such an increase of Treg is the compensatory mechanisms for the aggravation of liver inflammation. In support of this possibility, Bonelli *et al.* [33] reported that CD4+CD127–CD25– cells are increased in patients with systemic lupus erythematosus (SLE), the numbers of which are well correlated with disease activity. With regard to the ability of Treg in SLE patients, CD4+CD127–CD25– cells were potent in the inhibition of T

cell proliferation but not in IFN- γ release. Such a defective suppressor capacity may result in the continuation of tissue inflammation regardless of the presence of abundant Treg. The other conceivable role of CD4+CD25-CD127-FOXP3+ cells in active hepatitis may be a peripheral reservoir of CD4+CD25+FOXP3+ cells in case of flare-up of liver inflammation. In mice, it has been reported that CD25-FOXP3+ cells revert to CD25+FOXP3+ cells upon activation signals, thus leading to the expansion of the Treg pool [34]. In order to reach a definite conclusion on the role of CD127-CD25-FOXP3+ cells, further analyses are needed to elucidate whether these cells are inhibitory to either HCV-specific or HCV-nonspecific T cell responses.

Large-scale studies with HCV-infected patients demonstrated that the cumulative incidence of HCC in the PNALT group is extremely low compared with that in patients with apparent hepatitis and liver cirrhosis [35]. The lesser HCC incidence is also evident in patients who attained a lasting biochemical response to IFN-based therapy; even if they had failed to achieve sustained virological response [36]. These results clearly indicate that the maintenance of the PNALT state is one of the surrogate therapeutic goals in chronic HCV infection. Therefore, it is necessary to clarify the mechanisms of Treg induction in HCV infection, whether they are naturally or adaptively introduced, and to establish a feasible modality for controlling Treg. Our study has shown the importance of subset-oriented analyses of Treg for gaining access to that goal.

ACKNOWLEDGEMENT

This study was funded in part by Ministry of Education, Culture, Sports, Science and Technology, Ministry of Health, Labor and Welfare of Japan.

CONFLICT OF INTEREST

All of the authors do not have any commercial or other association that might pose a conflict of interest.

REFERENCES

- 1 Kasahara A, Hayashi N, Mochizuki K *et al*. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. *Hepatology* 1998; 27(5): 1394-1402.
- 2 Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. *Hepatology* 1997; 26 (3 Suppl. 1): 133S-136S.
- 3 Tassopoulos NC. Treatment of patients with chronic hepatitis C and normal ALT levels. *J Hepatol* 1999; 31 (Suppl. 1): 193-196.
- 4 Persico M, Persico E, Suozzo R *et al*. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. *Gastroenterology* 2000; 118(4): 760-764.
- 5 Suruki R, Hayashi K, Kusumoto K *et al*. Alanine aminotransferase level as a predictor of hepatitis C virus-associated hepatocellular carcinoma incidence in a community-based population in Japan. *Int J Cancer* 2006; 119(1): 192-195.
- 6 Nelson DR, Marousis CG, Davis GL *et al*. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. *J Immunol* 1997; 158(3): 1473-1481.
- 7 Schirren CA, Jung MC, Gerlach JT *et al*. Liver-derived hepatitis C virus (HCV)-specific CD4(+) T cells recognize multiple HCV epitopes and produce interferon gamma. *Hepatology* 2000; 32(3): 597-603.
- 8 Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. *Annu Rev Immunol* 2004; 22: 531-562.
- 9 Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. *J Exp Med* 2004; 199(7): 971-979.
- 10 Ehrenstein MR, Evans JG, Singh A *et al*. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. *J Exp Med* 2004; 200(3): 277-285.
- 11 Sugiyama H, Gyulai R, Toichi E *et al*. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. *J Immunol* 2005; 174(1): 164-173.
- 12 Weiss L, Donkova-Petrini V, Caccavelli L, Balbo M, Carbonneil C, Levy Y. Human immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. *Blood* 2004; 104(10): 3249-3256.
- 13 Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. *Cancer Res* 2005; 65(6): 2457-2464.
- 14 Jonuleit H, Schmitt E. The regulatory T cell family: distinct subsets and their interrelations. *J Immunol* 2003; 171(12): 6323-6327.
- 15 Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. *Science* 2003; 299(5609): 1057-1061.
- 16 Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. *Nat Immunol* 2005; 6(4): 331-337.
- 17 Cabrera R, Tu Z, Xu Y *et al*. An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. *Hepatology* 2004; 40(5): 1062-1071.
- 18 Rushbrook SM, Ward SM, Unitt E *et al*. Regulatory T cells suppress *in vitro* proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. *J Virol* 2005; 79(12): 7852-7859.
- 19 Sugimoto K, Ikeda F, Stadanlick J, Nunes FA, Alter HJ, Chang KM. Suppression of HCV-specific T cells without differential hierarchy demonstrated *ex vivo* in persistent HCV infection. *Hepatology* 2003; 38(6): 1437-1448.
- 20 Ward SM, Fox BC, Brown PJ *et al*. Quantification and localisation of FOXP3+ T lymphocytes and relation to

- hepatic inflammation during chronic HCV infection. *J Hepatol* 2007; 47(3): 316–324.
- 21 Chen W, Jin W, Hardegen N *et al.* Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. *J Exp Med* 2003; 198(12): 1875–1886.
 - 22 Liu W, Putnam AL, Xu-Yu Z *et al.* CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ Treg cells. *J Exp Med* 2006; 203(7): 1701–1711.
 - 23 Kuzushita N, Hayashi N, Moribe T *et al.* Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus. *Hepatology* 1998; 27(1): 240–244.
 - 24 Kanto T, Inoue M, Miyazaki M *et al.* Impaired function of dendritic cells circulating in patients infected with hepatitis C virus who have persistently normal alanine aminotransferase levels. *Intervirology* 2006; 49(1–2): 58–63.
 - 25 Leroy V, Vigan I, Mosnier JF *et al.* Phenotypic and functional characterization of intrahepatic T lymphocytes during chronic hepatitis C. *Hepatology* 2003; 38(4): 829–841.
 - 26 Penna A, Missale G, Lamonaca V *et al.* Intrahepatic and circulating HLA class II-restricted, hepatitis C virus-specific T cells: functional characterization in patients with chronic hepatitis C. *Hepatology* 2002; 35(5): 1225–1236.
 - 27 Boettler T, Spangenberg HC, Neumann-Haefelin C *et al.* T cells with a CD4+CD25+ regulatory phenotype suppress *in vitro* proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. *J Virol* 2005; 79(12): 7860–7867.
 - 28 Venken K, Hellings N, Thewissen M *et al.* Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. *Immunology* 2008; 123(1): 79–89.
 - 29 Bolacchi F, Sinistro A, Ciaprini C *et al.* Increased hepatitis C virus (HCV)-specific CD4+CD25+ regulatory T lymphocytes and reduced HCV-specific CD4+ T cell response in HCV-infected patients with normal versus abnormal alanine aminotransferase levels. *Clin Exp Immunol* 2006; 144(2): 188–196.
 - 30 Li S, Jones KL, Woollard DJ *et al.* Defining target antigens for CD25+ FOXP3+ IFN-gamma-regulatory T cells in chronic hepatitis C virus infection. *Immunol Cell Biol* 2007; 85(3): 197–204.
 - 31 Seddiki N, Santner-Nanan B, Martinson J *et al.* Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. *J Exp Med* 2006; 203(7): 1693–1700.
 - 32 You S, Leforban B, Garcia C, Bach JF, Bluestone JA, Chatenoud L. Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. *Proc Natl Acad Sci USA* 2007; 104(15): 6335–6340.
 - 33 Bonelli M, Savitskaya A, Steiner CW, Rath E, Smolen JS, Scheinecker C. Phenotypic and functional analysis of CD4+CD25- Foxp3+ T cells in patients with systemic lupus erythematosus. *J Immunol* 2009; 182(3): 1689–1695.
 - 34 Zelenay S, Lopes-Carvalho T, Caramalho I, Moraes-Fontes MF, Rebelo M, Demengeot J. Foxp3+ CD25- CD4 T cells constitute a reservoir of committed regulatory cells that regain CD25 expression upon homeostatic expansion. *Proc Natl Acad Sci USA* 2005; 102(11): 4091–4096.
 - 35 Okanoue T, Makiyama A, Nakayama M *et al.* A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. *J Hepatol* 2005; 43(4): 599–605.
 - 36 Tanaka H, Tsukuma H, Kasahara A *et al.* Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. *Int J Cancer* 2000; 87(5): 741–749.

Original Article

Effect of interferon α -2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis

Mika Kurokawa,¹ Naoki Hiramatsu,¹ Tsugiko Oze,¹ Kiyoshi Mochizuki,¹ Takayuki Yakushijin,¹ Nao Kurashige,¹ Yuko Inoue,¹ Takumi Igura,¹ Kazuho Imanaka,² Akira Yamada,³ Masahide Oshita,⁴ Hideki Hagiwara,⁵ Eiji Mita,⁶ Toshifumi Ito,⁷ Yoshiaki Inui,⁸ Taizo Hijioka,⁹ Harumasa Yoshihara,¹⁰ Atsuo Inoue,¹¹ Yasuharu Imai,¹² Michio Kato,⁶ Shinichi Kiso,¹ Tatsuya Kanto,¹ Tetsuo Takehara,¹ Akinori Kasahara¹ and Norio Hayashi¹

¹Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, ²Osaka Medical Center for Cancer and Cardiovascular Diseases, ³Hyogo Prefectural Nishinomiya Hospital, ⁴Osaka Police Hospital, ⁵Higashiosaka City Central Hospital, ⁶National Hospital Organization Osaka, ⁷Kansai Rousai Hospital, ⁸Hyogo Prefectural Nishinomiya Hospital, ⁹National Hospital Organization Osaka Minami Medical Center, ¹⁰Osaka Rousai Hospital, ¹¹Osaka General Medical Center and ¹²Ikeda Municipal Hospital, Osaka, Japan

Aim: The objective of this study was to elucidate the long-term effects of interferon (IFN) α -2b plus ribavirin combination therapy and to clarify whether this therapy can reduce the incidence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C.

Methods: A total of 403 patients infected with hepatitis C virus (HCV) were enrolled in a multicenter trial. All patients were treated with a combination of IFN- α -2b plus ribavirin therapy. We examined the incidence of HCC after combination therapy and analyzed the risk factors for liver carcinogenesis.

Results: A sustained virological response (SVR) was achieved by 139 (34%) of the patients. The cumulative rate of incidence of HCC was significantly lower in SVR patients than in non-SVR patients ($P = 0.03$), while there was no difference in the cumulative incidence of HCC between the transient response (TR) group and the no response (NR) group. Cox's

regression analysis indicated the following risk factors as independently significant in relation to the development of HCC: age being > 60 years ($P = 0.006$), advanced histological staging ($P = 0.033$), non-SVR to IFN therapy ($P = 0.044$). The cumulative incidence rate of HCC was significantly lower in patients who had average serum alanine aminotransferase (ALT) levels of < 40 IU/L than in those who showed average serum ALT levels of ≥ 40 IU/L after the combination therapy ($P = 0.021$).

Conclusions: These results suggest that the attainment of SVR or continuous normalization of ALT levels after IFN therapy can affect patients apart from HCC development.

Key words: chronic hepatitis C, continuous normalization of ALT, hepatocellular carcinoma, interferon plus ribavirin combination therapy, sustained virological response

INTRODUCTION

HEPATOCELLULAR CARCINOMA (HCC) is one of the most common malignancies in Japan and its incidence has been increasing over the last 30 years. Recently, various treatments such as transcatheter

arterial embolization/chemoembolization, radio frequency ablation and hepatic resection have been reported to yield significant improvements in overall patient survival,¹⁻³ but HCC relapse has thus far been observed in a majority of treated patients due to the highly malignant potential of the liver. In general, approximately 70–80% of Japanese HCC patients are also diagnosed with type C chronic hepatitis or cirrhosis.⁴ It has also been shown that the chronic hepatitis C (CHC) liver slowly but steadily progresses to cirrhosis^{5,6} and the risk of HCC increases according to the degree of liver fibrosis.^{7,8} In this regard, the success of treatment

Correspondence: Dr Naoki Hiramatsu, Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka 565-0871, Japan.
Email: hiramatsu@gh.med.osaka-u.ac.jp
Received 10 July 2008; revised 15 October 2008; accepted 2 November 2008.

for chronic hepatitis C virus (HCV) infection is expected to prevent the patient's liver from progressing to cirrhosis and to reduce the risk of development of HCC. Interferon (IFN) has been proven to be effective in reducing and in eliminating HCV from the circulation; in decreasing serum alanine aminotransferase (ALT) levels; and in improving the histological appearance of the liver in patients with CHC.⁹⁻¹¹ Moreover, it has been demonstrated that IFN monotherapy in CHC patients is associated with reducing the incidence of HCC, especially in those patients who achieved a sustained virological response (SVR).¹²⁻¹⁴ Recently, many investigators have reported that combination therapy using IFN- α -2b or pegylated IFN (Peg-IFN) N plus ribavirin is more effective for eradicating HCV than IFN monotherapy.¹⁵⁻¹⁷ However, it has not been accurately evaluated whether or not the combination therapy using Peg-IFN plus ribavirin could reduce HCC development in patients infected with HCV.

In this study, we evaluated the long-term effect of IFN- α -2b plus ribavirin therapy on the incidence of HCC in HCV-infected patients treated with the combination therapy by retrospective examination of the clinical outcomes.

METHODS

Patients

THIS STUDY WAS a multicenter trial conducted by Osaka University Hospital and other institutions participating in the Osaka Liver Forum in Japan. A total of 459 patients with HCV infection were treated with a combination of IFN- α -2b (Intron; Schering-Plough Corporation, Kenilworth, NJ, USA) plus ribavirin (Rebetol; Schering-Plough, Auxerre, France) between June 2002 and March 2005. All patients were treated with 6 MU of IFN- α -2b subcutaneously thrice a week and with oral ribavirin daily. Ribavirin was given at a total daily dose of 600 mg for patients who weighed < 60 kg and 800 mg for patients who weighed \geq 60 kg. Patients who were positive for hepatitis B surface antigen, anti-human immunodeficiency virus antibody or those with other liver diseases (alcoholic liver disease, autoimmune liver disease, etc) were excluded from this study. Also excluded were patients with a history of HCC and those who developed HCC within the first 6 months of the follow-up period after the end of IFN therapy, because of the possibility that microscopic HCC had been present before initiation of the treatment. The remaining 403 patients infected with HCV were enrolled and

followed in this study. The observation term was terminated upon the start of the next IFN therapy, such as Peg-IFN plus ribavirin after a combination of IFN- α -2b plus ribavirin therapy. Responses to IFN therapy were divided into the following three groups based on the viral load: sustained virological response (SVR) was defined as the absence of detectable serum HCV-RNA at 24 weeks after completion of IFN therapy. Transient response (TR) was defined as the absence of HCV-RNA from the serum at the end of treatment but detectable at 24 weeks after completion of therapy. Those categorized as having no response (NR) did not meet these criteria.

This study protocol followed the ethical guidelines of the 1975 Declaration of Helsinki, and informed consent was obtained from each patient.

Blood tests

Serum samples were stored frozen at -80°C . HCV-RNA levels were analyzed by quantitative reverse transcription (RT)-PCR assay (Amplacor-HCV version 2.0; Roche Diagnostic Systems, Tokyo, Japan). The lowest detection limit of this assay was 50 IU/mL. All patients were examined for serum HCV-RNA level and underwent hematological and biochemical tests just before therapy, every 4 weeks during treatment and every 12 weeks thereafter until the end of treatment.

Normal serum ALT is defined as < 40 IU/L. In addition, the biological response to IFN therapy was defined based on "the average serum ALT level", which was calculated from all data of ALT levels after completion of IFN therapy.

Histological evaluation

The patients underwent liver biopsies within 6 months before the start of therapy. Histopathological interpretation of specimens was done by experienced liver pathologists who had no clinical information. The histological appearance of the liver sample sections was evaluated according to METAVIR's histological score.¹⁸ Fibrosis stage was evaluated on a scale from 0 to 4.

Diagnosis and follow up of HCC

Ultrasonography was carried out before IFN therapy and every 3 to 6 months during the follow-up period. New space-occupying lesions detected or suspected at the time of ultrasonography were further examined by computed tomography (CT) or hepatic angiography. HCC was diagnosed by the presence of typical hypervascular characteristics on angiography, in addition to the findings from CT. If no typical image of HCC was observed, fine-needle aspiration biopsy was carried out with the

patient's consent, or the patient was carefully followed until a diagnosis was possible with a definite observation by CT or angiography.

Statistical analysis

Quantitative variables were expressed as mean \pm SD. The Kaplan–Meier method was used to calculate the cumulative incidence of HCC. The prognostic relevance of clinical variables and HCC incidence was evaluated by univariate analysis with log-rank test and by multivariate Cox's regression analysis. A value of $P < 0.05$ (two-tailed) was considered to indicate significance. All calculations were performed with SPSS version 15.0J (SPSS, Chicago, IL, USA).

RESULTS

Baseline characteristics in patients treated with interferon therapy

THE BASELINE CLINICAL features of the enrolled patients are shown in Table 1. The mean age of the patients was 55.8 ± 10.9 years, and 64% of the total cases were male. Two hundred and sixty-one patients (73%) were infected with HCV genotype 1 and had a viral load of more than 10^5 IU/ml. Liver biopsy was done for 320 cases and the ratio of patients with severe fibrosis (F3–4) diagnosed by the HAI score was more than 31%. The mean platelet count was $14.8 \pm 5.1 \times 10^4/\mu\text{l}$, and the ALT level was 96.0 ± 62.6 IU/L. A sustained virological response (SVR) was achieved by 139 patients (34%) by combination therapy of IFN- α -2b

Table 1 Baseline characteristics in patients treated with interferon therapy

	All cases
Number of patients	403
Age	55.8 ± 10.9
Gender (male/female)	257/145
Genotype and viral load (1H/non-1H)	261/97
Fibrosis (F0/1/2/3/4)	15/149/56/92/8
WBC ($/\mu\text{l}$)	5113 ± 1487
Platelet ($\times 10^4/\mu\text{l}$)	14.8 ± 5.1
ALT (IU/l)	96.0 ± 62.6
IFN effect (SVR/TR/NR/cessation)	139/109/110/45

Data are number of patients, mean \pm standard deviation. Fibrosis stage is evaluated on a scale from 0 to 4 according to METAVIR's histological score. 1H, Genotype 1 and high viral load; non-1H, all except for 1H; ALT, alanine aminotransferase; IFN, interferon; NR, no response; SVR, sustained virological response; TR, transient response; WBC, white blood cells.




Figure 1 Cumulative incidence of development of hepatocellular carcinoma (HCC) according to treatment effect: (—) sustained virological response; (.....) non-sustained virological response.

plus ribavirin. According to an intent-to-treat analysis, 20% (51/261) of patients with HCV genotype 1 and a high viral load ($\geq 100\text{KIU}/\text{mL}$) achieved SVR by the combination therapy, whereas 75% (73/97) of the patients with HCV genotype 2 or a low load showed SVR. The median observation period for all patients was 36.5 ± 14.8 months with a range of 6 to 62 months from the end-point of IFN treatment.

Cumulative incidence of development of HCC according to the treatment effect (SVR vs. non-SVR)

Figure 1 shows the Kaplan–Meier estimates of the cumulative HCC incidence according to the treatment effect (SVR vs. non-SVR). Twenty-five (6%) of the 403 enrolled patients developed HCC; four (2.9%) of the SVR group and 21 (8.0%) of the non-SVR group. The cumulative incidence rate of HCC was significantly lower in patients of the SVR group than in those of the non-SVR group ($P = 0.03$).

Cumulative incidence of HCC development according to the treatment effect (SVR vs. TR vs. NR vs. cessation)

Figure 2 shows the Kaplan–Meier estimates of the cumulative HCC incidence according to the treatment effect (SVR vs. TR vs. NR vs. cessation). Five patients (4.6%) of the TR group, nine (8.2%) of the NR group and seven (15.6%) of the cessation group developed




Figure 2 Cumulative incidence of hepatocellular carcinoma (HCC) development according to treatment effect: (—) sustained virological response; (.....) transient response group; (- -) no response; (- ·) cessation.

HCC. There was no significant difference in the cumulative incidence of HCC between the TR and NR groups ($P = 0.394$). In contrast, the cumulative incidence rate of HCC was significantly lower in patients of the SVR group than in those of the NR group ($P = 0.05$). These results indicate that treatment of the TR group with IFN- α -2b plus ribavirin therapy did not reduce HCC development when compared to the NR group.

Risk factors for cumulative incidence of HCC development

Univariate analysis with the log-rank test showed that the following were significant risk factors for the development of HCC; older age (> 65 years) ($P = 0.01$), severe fibrosis ($P = 0.006$), high platelet count ($> 14 \times 10^4/\mu\text{l}$) ($P = 0.017$) and non-SVR ($P = 0.03$).

Stepwise multivariate analyses of these four variables were performed for all patients treated with combination therapy of IFN- α -2b plus ribavirin by Cox's regression analysis, as shown in Table 2. The analysis indicated the following factors as independent significant risk factors related to the development of HCC: older age (risk ratio, 3.23; 95% CI, 1.37–8.56; $P = 0.006$), fibrosis staging (risk ratio, 1.69; 95% CI, 1.04–2.67; $P = 0.033$) and non-SVR to IFN therapy (risk ratio, 3.57; 95% CI, 1.04–12.36; $P = 0.044$).

Cumulative incidence of HCC development according to average serum ALT levels after combination therapy

The average serum ALT levels in 134 patients (96.4%) of the SVR group were < 40 IU/L after completion of the combination therapy, while 63 patients (24.4%) of the non-SVR group showed serum ALT levels of ≥ 40 IU/L. Figure 3 shows Kaplan-Meier estimates of the cumulative HCC incidence according to the average serum ALT levels after combination therapy. The cumulative incidence rate of HCC was significantly lower in patients with average serum ALT levels of < 40 IU/L than with average serum ALT levels of ≥ 40 IU/L ($P = 0.021$).

Cumulative incidence of HCC development according to the treatment effect (SVR vs. non-SVR) in patients showing less than 40 IU/L average ALT levels after the combination therapy

Figure 4 shows Kaplan-Meier estimates of the cumulative HCC incidence according to the treatment effect (SVR vs. non-SVR) in patients who showed less than 40 IU/L average ALT levels after the combination therapy. There was no significant difference in the cumulative incidence rate of HCC between the SVR and non-SVR groups ($P = 0.37$).

Table 2 Risk factors for cumulative incidence of HCC development

Variable	Category	Risk ratio	<i>P</i> value	95% CI
Gender	male	1		
	female	0.34	0.053	0.11–1.01
Age (years)	65 <	1		
	65 \geq	3.23	0.006	1.37–8.56
Fibrosis	F0/1/2/3/4	1.69	0.033	1.04–2.67
IFN therapy	Non-SVR	1		
	SVR	0.28	0.044	1.04–12.36

CI, confidence interval; IFN, interferon; SVR, sustained virological response.




Figure 3 Cumulative incidence of HCC development according to average alanine aminotransferase (ALT) levels after the combination therapy. (—) ALT < 40 IU/ml; (.....) ALT > 40 IU/ml.

DISCUSSION

COMBINATION THERAPIES USING IFN- α -2b or Peg-IFN plus ribavirin have been proven to be more effective in treating for HCV infection than IFN monotherapy.¹⁵⁻¹⁷ However, it has not been accurately




Figure 4 Cumulative incidence of hepatocellular carcinoma (HCC) development according to the treatment effect in patients who showed less than 40 IU/L average alanine aminotransferase (ALT) levels after the combination therapy. (—) Sustained virological response; (.....) non-sustained virological response.

evaluated whether the combination therapies using IFN- α -2b or Peg-IFN plus ribavirin could reduce the development of HCC, and what the risk factors of HCC incidence were in patients infected with HCV. In this study, we retrospectively examined the incidence of HCC with IFN- α -2b plus ribavirin therapy to clarify the indicators of combination therapy for reducing HCC in patients infected with HCV. We also evaluated whether or not SVR or continuous normalization of ALT levels could reduce the risk of development of HCC.

Previous studies have demonstrated that IFN monotherapy has a preventive effect on the development of HCC, especially in patients with SVR.¹²⁻¹⁴ In this study, using the combination of IFN- α -2b plus ribavirin, we obtained almost the same result for the SVR group treated with IFN- α -2b plus ribavirin therapy, which showed a significantly lower possibility of HCC development over a long-term period when compared with the non-SVR group. In contrast, we found no difference in the cumulative incidence of HCC between the TR and NR groups, while Kasahara *et al.* reported that the cumulative incidence of HCC in patients who achieved TR by IFN monotherapy was significantly lower than those with NR.¹³ Recent reports have demonstrated that the combination therapy of IFN- α -2b plus ribavirin is able to induce a SVR in a significant proportion of patients with IFN monotherapy-resistant chronic hepatitis C,^{19,20} suggesting that a viral relapse after IFN therapy is efficiently suppressed by combination with ribavirin. Since the combination therapy was a more effective treatment for HCV infection than IFN monotherapy¹⁵⁻¹⁷ and there are fewer TR patients with combination therapy than with monotherapy, we speculate that not all, but quite a few patients of the TR group given IFN monotherapy corresponded to the SVR group given the combination therapy, and that the TR group given the combination therapy might have been included in the NR group of IFN monotherapy. This would mean that the "TR group given combination therapy" should be distinguished from the "TR group given IFN monotherapy", and might explain why the results of this study were inconsistent with previous reports of the cumulative incidence of HCC in the TR group given IFN monotherapy being significantly lower than those with NR.¹³

The Kaplan-Meier method showed that older age (> 65 years), severe fibrosis (F2-4), high platelet count (> 14×10^4) and non-SVR were significantly associated with the development of HCC. The Cox's regression analysis indicated that older age, fibrosis staging and non-SVR to IFN therapy were significant risk factors related to the development of HCC. These results were

almost comparable with those of previous reports using IFN monotherapy^{12-14,21} and IFN plus ribavirin combination therapy,²²⁻²⁴ suggesting that the factors associated with the development of HCC are common among these treatments and that patients of older age, with advanced fibrosis and showing non-SVR to IFN therapy should be followed up carefully for longer periods, even if IFN therapy could be performed completely. In addition, four of the SVR group patients developed HCC at more than 6 months after the treatment, which means these patients need careful follow-up even if SVR has been achieved.²⁵

The incidence of HCC has been reported to be lower in patients with normal ALT levels, even if serum HCV-RNA was positive 6 or 12 months after IFN monotherapy, when compared to those without a biochemical response,^{13,26,27} suggesting that the aim of IFN therapy for patients infected with HCV should be not only HCV eradication, but also the achievement of a biochemical response in order to reduce the incidence of HCC. In this study, we divided the patients into two groups, one with persistently normal serum ALT levels and the other with elevated serum ALT levels based on "the average serum ALT levels" after completion of IFN therapy. We then evaluated the cumulative HCC incidence of each group using the Kaplan-Meier estimation. Our data showed that patients with continuous normalization of ALT levels have a lower possibility of HCC development than those showing elevated ALT after the combination therapy, suggesting that continuous normalization of ALT levels after the combination therapy is an important factor for reducing HCC development. Interestingly, based on the Kaplan-Meier estimates of the cumulative HCC incidence according to the treatment effect in patients who showed less than 40 IU/L average ALT levels after the combination therapy, we found no difference in HCC incidence rates between the SVR group and non-SVR group. Figure 1 shows that the combination therapy is strongly associated with a reduced incidence of HCC in the patients who attain SVR, which seems to be a means for achieving normalization of serum ALT levels in HCV patients. However, it was also shown that, even in the non-SVR group, patients with persistently normal serum ALT levels achieved a reduced risk of HCC development. Taken together, our aim of treatment for patients infected with HCV is to primarily completely eradicate HCV. Next, for the non-SVR group patients, we would speculate that maintaining normalization of ALT levels by some other treatments may prevent HCC development in HCV-infected patients with abnormal serum ALT levels even if

SVR is not achieved. Other treatments should be used to decrease serum ALT levels to below the upper limit of the normal range. Hopefully, the new treatments such as those with protease inhibitors can be helpful for these patients.²⁸

Although IFN monotherapy in CHC patients has been demonstrated to be associated with reducing the incidence of HCC, especially in patients who attain SVR,¹²⁻¹⁴ what actually occurs in IFN plus ribavirin combination therapy has not been clarified and the indicator for reducing HCC in patients infected with HCV has not been defined. We showed that this combination therapy could reduce the incidence of HCC and that older age, severe fibrosis and non-SVR were risk factors for HCC development. This therapy can increase the SVR patient ratio, and SVR or continuous normalization of ALT levels after combination therapy using IFN- α -2b plus ribavirin reduce the incidence of HCC in patients with HCV infection. Therefore, this therapy can not only avert the advance of the disease toward liver cirrhosis, but also decrease the risk of HCC. IFN plus ribavirin combination therapy is beneficial for HCV patients from both aspects. In conclusion, the present study shows that the attainment of SVR or continuous normalization of serum ALT levels induced by the combination therapy has a significantly beneficial effect on the clinical course of HCV patients by decreasing the incidence of HCC.

REFERENCES

- 1 Takayasu K, Arii S, Ikai I *et al.* Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. *Gastroenterology* 2006; 131: 461-9.
- 2 Taura K, Ikai I, Hatano E, Fujii H, Uyama N, Shimahara Y. Implication of frequent local ablation therapy for intrahepatic recurrence in prolonged survival of patients with hepatocellular carcinoma undergoing hepatic resection: an analysis of 610 patients over 16 years old. *Ann Surg* 2006; 244: 265-73.
- 3 Shimada K, Sano T, Sakamoto Y, Kosuge T. A long-term follow-up and management study of hepatocellular carcinoma patients surviving for 10 years or longer after curative hepatectomy. *Cancer* 2005; 104: 1939-47.
- 4 Kiyosawa K, Tanaka E, Sodeyama T. Hepatitis C virus and hepatocellular carcinoma. In: Reesink HW, ed. *Current Studies in Hematology Blood Transfusion*. Basel: Karger, 1998; 161-80.
- 5 Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic post-transfusion hepatitis. *Hepatology* 1991; 14: 969-74.

- 6 Tong MJ, el-Farra NS, Reikes AR, Co, RL. Clinical outcome after transfusion-associated hepatitis C. *N Engl J Med* 1995; 332: 1463-6.
- 7 Yoshida H, Shiratori Y, Moriyama M *et al*. Interferon therapy reduces the risk of hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. *Ann Intern Med* 1999; 131: 174-81.
- 8 Okanoue T, Itoh Y, Minami M *et al*. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. *J Hepatol* 1999; 30: 653-9.
- 9 Hagiwara H, Hayashi N, Mita E *et al*. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. *Gastroenterology* 1993; 104: 877-83.
- 10 Davis GL, Balart LA, Schiff ER *et al*. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized controlled trial. *N Engl J Med* 1989; 321: 1501-6.
- 11 Hiramatsu N, Hayashi N, Kasahara A *et al*. Improvement of liver fibrosis in chronic hepatitis C patients treated with natural Interferon alpha. *J Hepatol* 1995; 22: 135-42.
- 12 Ikeda K, Saitoh S, Arase Y *et al*. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis C. A long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. *Hepatology* 1999; 29: 1124-9.
- 13 Kasahara A, Hayashi N, Mochizuki K *et al*. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. *Hepatology* 1998; 27: 1394-402.
- 14 Nishiguchi S, Kuroki T, Nakatani S *et al*. Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. *Lancet* 1995; 346: 1051-5.
- 15 McHutchison JG, Gordon SC, Schiff ER *et al*. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. *N Engl J Med* 1998; 339: 1485-92.
- 16 Fried MW, Shiffman ML, Reddy KR *et al*. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002; 347: 975-82.
- 17 Manns MP, McHutchinson JG, Gordon SC *et al*. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. *Lancet* 2001; 358: 958-65.
- 18 The METAVIR Cooperative Group. Inter- and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C. *Hepatology* 1994; 20: 15-20.
- 19 Poynard T, Marcellin P, Lee SS *et al*. Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Interventional Therapy Group (IHIT). *Lancet* 1998; 352: 1426-32.
- 20 Davis GL, Esteban-Mur R, Rustgi V *et al*. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. *N Engl J Med* 1998; 339: 1493-9.
- 21 Makiyama A, Itoh Y, Kasahara A *et al*. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. *Cancer* 2004; 101: 1616-22.
- 22 Hung CH, Lee CM, Lu SN *et al*. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. *J Viral Hepat* 2006; 13: 409-14.
- 23 Namiki I, Asahina Y, Kurosaki M *et al*. Development of hepatocellular carcinoma after interferon therapy in chronic hepatitis C. *Intervirology* 2005; 48: 59-63.
- 24 Yu ML, Lin SM, Chuang WL *et al*. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. *Antivir Ther* 2006; 11: 985-94.
- 25 Ikeda M, Fujiyama S, Tanaka M *et al*. Clinical features of hepatocellular carcinoma that occur after sustained virological response to interferon for chronic hepatitis C. *J Gastroenterol Hepatol* 2006; 21: 122-8.
- 26 Arase Y, Ikeda K, Suzuki F *et al*. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection. *J Med Virol* 2007; 79: 1485-90.
- 27 Suzuki K, Ohkoshi S, Yano M *et al*. Sustained biochemical remission after interferon treatment may closely be related to the end of treatment biochemical response and associated with a lower incidence of hepatocarcinogenesis. *Liver Int* 2003; 23: 143-7.
- 28 Sarrazin C, Rouzier R, Wagner F *et al*. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. *Gastroenterology* 2007; 132: 1270-8.

Pegylated interferon alpha-2b (Peg-IFN α -2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN α -2b plus ribavirin

T. Oze,^{1,*} N. Hiramatsu,^{1,*} T. Yakushijin,¹ M. Kurokawa,¹ T. Igura,¹ K. Mochizuki,¹ K. Imanaka,² A. Yamada,³ M. Oshita,⁴ H. Hagiwara,⁵ E. Mita,⁶ T. Ito,⁷ Y. Inui,⁸ T. Hijioka,⁹ S. Tamura,¹⁰ H. Yoshihara,¹¹ E. Hayashi,¹² A. Inoue,¹³ Y. Imai,¹⁴ M. Kato,¹⁵ Y. Yoshida,¹ T. Tatsumi,¹ K. Ohkawa,¹ S. Kiso,¹ T. Kanto,¹ A. Kasahara,¹ T. Takehara¹ and N. Hayashi¹

¹Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Yamadaoka, Suita, Osaka, Japan; ²Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Osaka, Japan; ³Sumitomo Hospital, Osaka, Osaka, Japan; ⁴Osaka Police Hospital, Osaka, Osaka, Japan; ⁵Higashiosaka City Central Hospital, Higashiosaka, Osaka, Japan; ⁶National Hospital Organization Osaka National Hospital, Osaka, Osaka, Japan; ⁷Kansai Rousai Hospital, Amagasaki, Hyogo, Japan; ⁸Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Hyogo, Japan; ⁹National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka, Japan; ¹⁰Minoh City Hospital, Minoh, Osaka, Japan; ¹¹Osaka Rousai Hospital, Sakai, Osaka, Japan; ¹²Kinki Central Hospital of Mutual Aid Association of Public School Teachers, Itami, Hyogo, Japan; ¹³Osaka General Medical Center, Osaka, Osaka, Japan; ¹⁴Ikeda Municipal Hospital, Ikeda, Osaka, Japan; and ¹⁵National Hospital Organization Minami Wakayama Medical Center, Tanabe, Wakayama, Japan

Received November 2008; accepted for publication December 2008

SUMMARY. Chronic hepatitis C (CH-C) genotype 1 patients who achieved early virologic response have a high probability of sustained virologic response (SVR) following pegylated interferon (Peg-IFN) plus ribavirin therapy. This study was conducted to evaluate how reducing drug doses affects complete early virologic response (c-EVR) defined as hepatitis C virus (HCV) RNA negativity at week 12. Nine hundred eighty-four patients with CH-C genotype 1 were enrolled. Drug doses were evaluated independently on a body weight base from doses actually taken. From multivariate analysis, the mean dose of Peg-IFN α -2b during the first 12 weeks was the independent factor for c-EVR ($P = 0.02$), not ribavirin. The c-EVR rate was 55% in patients receiving ≥ 1.2 $\mu\text{g}/\text{kg}/\text{week}$ of Peg-IFN, and declined to 38% at 0.9–1.2 $\mu\text{g}/\text{kg}/\text{week}$, and 22% in patients given < 0.9 $\mu\text{g}/\text{kg}/\text{week}$ ($P < 0.0001$). Even with stratified analysis according to

ribavirin dose, the dose-dependent effect of Peg-IFN on c-EVR was observed, and similar c-EVR rates were obtained if the dose categories of Peg-IFN were the same. Furthermore, the mean dose of Peg-IFN during the first 12 weeks affected HCV RNA negativity at week 24 ($P < 0.0001$) and SVR ($P < 0.0001$) in a dose-dependent manner. Our results suggest that Peg-IFN was dose-dependently correlated with c-EVR, independently of ribavirin dose. Thus, maintaining the Peg-IFN dose as high as possible during the first 12 weeks can yield HCV RNA negativity and higher c-EVR rates, leading to better SVR rates in patients with CH-C genotype 1.

Keywords: chronic hepatitis C, drug dose, early virologic response, HCV RNA negativity, pegylated interferon plus ribavirin, sustained virologic response.

Abbreviations: c-EVR, complete EVR; CH-C, chronic hepatitis C; EVR, early virologic response; G-CSF, granulocyte-macrophage colony stimulating factor; Hb, haemoglobin; HCV, hepatitis C virus; Peg-IFN, pegylated interferon; Plt, platelet; SVR, sustained virologic response; WBC, white blood cell.

Correspondence: Naoki Hiramatsu, MD, PhD, Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita City, Osaka 565-0871, Japan. E-mail hiramatsu@gh.med.osaka-u.ac.jp

*These authors contributed equally to this work.

INTRODUCTION

Pegylated interferon (Peg-IFN) plus ribavirin therapy can improve anti-viral efficacy for patients with chronic hepatitis C [1–5], and the prognosis of patients in whom hepatitis C virus (HCV) is successfully eradicated improves markedly [6–10]. However, HCV still persists in approximately half of genotype 1 patients treated with Peg-IFN plus ribavirin [2–4]. Therefore, the treatment method needs to be well managed in order to maximize the virologic response in these patients with HCV genotype 1.

In order to achieve sustained virologic response (SVR), earlier virologic response is very important for patients with chronic hepatitis C (CH-C) genotype 1. A high SVR rate (65–72%) was found in patients who achieved early virologic response (EVR) defined as a 2-log decrease in HCV RNA level at week 12, but only 0–3% SVR was seen in patients without EVR [3,11]. Additionally, complete EVR (c-EVR), which means HCV RNA negativity at week 12, is more strongly related to SVR [3].

The relationship between drug exposure and anti-viral effect has been reported in several papers [2,11–15]. McHutchison *et al.* [12] demonstrated that the SVR rate in patients who received $\geq 80\%$ of their total planned doses of Peg-IFN and ribavirin for $\geq 80\%$ of the scheduled duration of therapy was significantly higher than that of patients who received $< 80\%$ of one or both drugs (51% vs 34%) and also suggested that the impact of dose reduction was greatest in patients for whom the dose had to be decreased within the first 12 weeks of treatment. In a subsequent analysis, reducing the dose of Peg-IFN and ribavirin to $< 80\%$ of the full planned dose within the first 12 weeks was reported to reduce EVR rate from 80 to 33% [11]. Thus, drug adherence during the first 12 weeks has been shown to be very important for attaining EVR and SVR, but it remains obscure whether either drug can be reduced to a certain degree without adversely affecting the treatment efficacy.

In the present study, we examined the correlation between c-EVR and drug doses which are evaluated on a body weight basis from drug doses actually taken, in order to clarify the necessary drug exposure of Peg-IFN and ribavirin for achieving a higher c-EVR rate in patients with CH-C genotype 1.

PATIENTS AND METHODS

Patients

The current study was a retrospective, multicenter trial conducted by Osaka University Hospital and other institutions participating in the Osaka Liver Forum. A total of 984 patients with CH-C treated with a combination of Peg-IFN α -2b plus ribavirin were enrolled in this study between December 2004 and September 2006. The baseline characteristics of the patients are summarized in Table 1. All patients were Japanese, their mean age was 56.3 ± 10.1 years, and 56% were males. The mean serum alanine aminotransferase level was 79 ± 61 IU/L.

Patients eligible for this study were those who were infected with HCV genotype 1 and had a viral load of more than 10^5 IU/mL, but were negative for hepatitis B surface antigen or anti-human immunodeficiency virus. Patients were excluded from this study if they had decompensated cirrhosis or other forms of liver disease (alcohol liver disease, autoimmune hepatitis). Informed consent was obtained from each patient included in this study. This study was conducted according to the ethical guidelines of the 1975 Dec-

Table 1 Baseline characteristics of patients

Factor	Mean \pm SD or number
<i>n</i>	984
Age (year)	56.3 ± 10.1
Sex: male/female	555/429
Body weight (kg)	61.8 ± 11.5
History of interferon treatment	
Naïve/experienced	575/409(160/182)
(relapser/nonresponder)*	
White blood cells (per mm ³)	5052 ± 1550
Neutrophils (per mm ³)	2577 ± 1092
Red blood cells ($\times 10^4$ /mm ³)	442 ± 47
Haemoglobin (g/dL)	14.1 ± 1.4
Platelets ($\times 10^4$ /mm ³)	15.9 ± 5.5
AST (IU/L)	66 ± 45
ALT (IU/L)	79 ± 61
Serum HCV RNA (kIU/mL) [†]	1600
Histology (METAVIR) [‡]	
Fibrosis; 0/1/2/3/4	49/314/197/105/18
Activity; 0/1/2/3	23/329/304/27

AST, aspartate aminotransferase; ALT, alanine aminotransferase; HCV, hepatitis C virus.

*Viral response to previous treatment was unknown in 57 patients, and 10 patients had discontinued treatment. [†]Data shown are median values. [‡]301 missing.

laration of Helsinki and informed consent was obtained from each patient.

Treatment

All patients received Peg-IFN α -2b (PEGINTRON; Schering-Plough, Kenilworth, NJ, USA) plus ribavirin (REBETOL; Schering-Plough) for the duration of the study of 48 weeks. Peg-IFN α -2b was given subcutaneously once weekly at a dosage of 60–150 μ g/kg based on body weight (body weight 35–45 kg, 60 μ g; 46–60 kg, 80 μ g; 61–75 kg, 100 μ g; 76–90 kg, 120 μ g; 91–120 kg, 150 μ g) and ribavirin was given orally twice a day at a total dose of 600–1000 mg/day based on body weight (body weight ≤ 60 kg, 600 mg; 60–80 kg, 800 mg; > 80 kg, 1000 mg), according to a standard treatment protocol for Japanese patients.

Dose reduction

Dose modification followed, as a rule, the manufacturer's drug information according to the intensity of the haematological adverse effects. The dose of Peg-IFN α -2b was reduced to 50% of the assigned dose if the white blood cell (WBC) count declined to < 1500 /mm³, the neutrophil count to < 750 /mm³ or the platelet (Plt) count to $< 8 \times 10^4$ /mm³, and was discontinued if the WBC count declined to < 1000 /

mm³, the neutrophil count to <500/mm³ or the Plt count to <5 × 10⁴/mm³. Ribavirin was also reduced from 1000 to 600 mg, or 800 to 600 mg, or 600 to 400 mg if the haemoglobin (Hb) level decreased to <10 g/dL, and was discontinued if the Hb level decreased to <8.5 g/dL. Both Peg-IFN α -2b and ribavirin had to be discontinued if there was a need to discontinue one of the drugs. During this therapy, ferric medicine or haematopoietic growth factors, such as erythropoietin alpha, or granulocyte-macrophage colony stimulating factor (G-CSF), were not administered.

Virologic assessment and definition of virologic response

Serum HCV RNA level was quantified using the COBAS AMPLICOR HCV MONITOR test, version 2.0 (detection range 6–5000 kIU/mL; Roche Diagnostics, Branchburg, NJ, USA) and qualitatively analysed using the COBAS AMPLICOR HCV test, version 2.0 (lower limit of detection 50 IU/mL). The c-EVR was defined as the absence of detectable serum HCV RNA at treatment week 12, and SVR was defined as the absence of detectable serum HCV RNA at week 72. Patients with less than a 2-log decrease in HCV RNA level at treatment week 12 compared with the baseline had to stop treatment and were regarded as nonresponders. All patients with detectable serum HCV RNA at treatment week 24 were also considered nonresponders and excluded from further treatment.

Assessment of drug exposure

The amounts of Peg-IFN α -2b and ribavirin actually taken by each patient during the first 12 weeks of the treatment were evaluated by reviewing the medical records. The mean doses of both drugs were calculated individually as averages on the basis of body weight at baseline: Peg-IFN α -2b expressed as μ g/kg/week, and ribavirin expressed as mg/kg/day.

Evaluation of impact of drug exposure on c-EVR

We evaluated the relationship between the drug exposure of both drugs and c-EVR by univariate and multivariate analysis for c-EVR, using the factors of mean administration doses of both drugs during the first 12 weeks and the factors at baseline. Furthermore, Peg-IFN α -2b dose (average dose per body weight and per week) was classified into five categories (up to 0.6 μ g/kg; from 0.6 to <0.9 μ g/kg; from 0.9 to <1.2 μ g/kg; from 1.2 to <1.5 μ g/kg; from 1.5 μ g/kg and above). Ribavirin exposure was classified into four categories (up to 8 mg/kg; from 8 to <10 mg/kg; from 10 to <12 mg/kg; from 12 mg/kg and above), in order to examine the impact of Peg-IFN dose exposure on c-EVR. This impact was also evaluated based on the percentage of the total prescribed dose and compared with that based on the mean dose per body weight.

Statistical analysis

Baseline data for various demographic, biochemical and virologic characteristics of the patients are expressed as mean \pm SD or median values. To analyse the relationship between baseline data including drug exposure and c-EVR, univariate analysis using the Mann–Whitney *U*-test or chi-squared test and multivariate analysis using logistic regression analysis were performed. The significance of trends in values was determined with the Mantel–Haenszel chi-square test. A two-tailed *P*-value < 0.05 was considered significant. Statistical analysis was conducted with SPSS version 15.0J (SPSS Inc., Chicago, IL, USA).

RESULTS

Progress of patients treated with Peg-IFN α -2b and ribavirin

Of the 984 patients, 81 discontinued treatment because of adverse events (*n* = 74) or voluntary withdrawal (*n* = 7) by treatment week 12. The 903 patients who completed 12 weeks of treatment were assessed for c-EVR. During 12–48 weeks of treatment, 331 of the nonresponders and nine of breakthrough discontinued treatment, as did 91 patients (adverse events, *n* = 71; voluntary withdrawal, *n* = 20). A total of 472 patients completed 48 weeks of treatment.

Drug reduction and virologic response

Peg-IFN α -2b was reduced without discontinuation in 29% (*n* = 266) and ribavirin was reduced without discontinuation in 40% (*n* = 359) of the 903 patients who completed 12 weeks of treatment. The c-EVR rate was 49% (445/903) and HCV RNA was negative at week 24 in 60% (542/903) of patients who completed 12 weeks of treatment. Of the 445 patients with c-EVR, 327 patients achieved SVR (73%). Only 7% of the 458 patients without c-EVR did so.

Impact of dose exposure of Peg-IFN α -2b and ribavirin on c-EVR

The mean dose of Peg-IFN α -2b actually taken during the first 12 weeks by each patient was 1.33 μ g/kg/week (range 0.41–2.16 μ g/kg/week; median 1.40 μ g/kg/week) and that of ribavirin was 10.4 mg/kg/day (range 2.9–16.2 mg/kg/day; median 10.6 mg/kg/day).

The mean doses of both drugs and the factors at baseline correlated with the c-EVR were assessed by univariate and multivariate logistic regression analyses. Univariate analysis showed that factors significantly associated with c-EVR were age, sex, WBC, neutrophils, red blood cells, Hb, Plt, aspartate aminotransferase, the degree of liver fibrosis and the mean doses of Peg-IFN α -2b and ribavirin during the first 12 weeks (Table 2). The factors selected as significant by the univari-

Table 2 Univariate analysis for c-EVR among patients who completed 12 weeks treatment

Factor	c-EVR (+)	c-EVR (-)	P-value
<i>n</i>	445	458	
Age (year)	54.4 ± 10.4	57.5 ± 9.6	<0.001
Sex: male/female	267/178	237/221	0.01
Serum HCV RNA (kIU/mL)*	1500	1600	0.28
White blood cells (per mm ³)	5336 ± 1536	4818 ± 1547	<0.001
Neutrophils (per mm ³)	2789 ± 1133	2398 ± 1038	<0.001
Red blood cells (×10 ⁴ /mm ³)	450 ± 46	435 ± 49	<0.001
Haemoglobin (g/dL)	14.3 ± 1.4	13.9 ± 1.4	<0.001
Platelets (×10 ⁴ /mm ³)	17.3 ± 5.2	15.0 ± 5.6	<0.001
AST (IU/L)	62 ± 44	69 ± 44	<0.001
ALT (IU/L)	77 ± 64	80 ± 57	0.07
Histology (METAVIR) [†]			
Fibrosis: 0–2/3–4	273/37	247/74	<0.001
Activity: 0–1/2–3	171/139	159/162	0.16
Peg-IFN dose (µg/kg/week) [‡]	1.39 ± 0.22	1.28 ± 0.30	<0.001
Ribavirin dose (mg/kg/day) [‡]	10.6 ± 1.7	10.1 ± 2.1	0.002

c-EVR, complete early virologic response; HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; Peg-IFN, pegylated interferon. *Data shown are median values. [†]272 missing. [‡]Mean doses during 0–12 weeks.

Table 3 Multivariate analysis for c-EVR among patients who completed 12 weeks treatment

Factor	Category	Odds ratio	95% CI	P-value
Age	by 1 year	0.982	0.966–0.999	0.04
Sex	male/female	–	–	NS
Neutrophils	by 100/mm ³	1.017	1.002–1.033	0.03
Red blood cells	by 1 × 10 ⁴ /mm ³	–	–	NS
Haemoglobin	by 1 g/dL	–	–	NS
Platelets	by 1 × 10 ⁴ /mm ³	1.051	1.014–1.088	<0.01
AST	by 1 IU/L	–	–	NS
Fibrosis*	0–2/3–4	–	–	NS
Peg-IFN dose [‡]	by 0.1 µg/kg/week	1.079	1.011–1.151	0.02
Ribavirin dose [‡]	by 1 mg/kg/day	–	–	NS

95% CI, 95% confidence interval; Peg-IFN, c-EVR, complete early virologic response; pegylated interferon; N.S., No Significant difference; AST, aspartate aminotransferase.

*METAVIR fibrosis score. [‡]Mean doses during 0–12 weeks.

ate analysis were evaluated by multivariate logistic regression analysis. The mean dose of Peg-IFN α -2b during the first 12 weeks was the independent factor for c-EVR ($P = 0.02$), apart from the neutrophils ($P = 0.03$) and Plt value at baseline ($P < 0.01$) and age ($P = 0.04$) (Table 3). In contrast, the mean dose of ribavirin during the first 12 weeks showed no correlation with c-EVR.

The c-EVR rates were 54% (137/253) and 56% (246/443) for patients who received ≥ 1.5 and 1.2–1.5 µg/kg/week of Peg-IFN α -2b on average during the first 12 weeks, and declined to an average rate of 38% (40/105) in patients given 0.9–1.2 µg/kg/week of Peg-IFN α -2b, and an average rate of 22% (22/102) in patients given < 0.9 µg/kg/week ($P < 0.0001$) (Table 4). The c-EVR rate among the patients

with ≥ 1.2 µg/kg/week of Peg-IFN α -2b was significantly higher than that of the patients with < 1.2 µg/kg/week [≥ 1.2 µg/kg/week, 55% (383/696) vs < 1.2 µg/kg/week, 30% (62/207), $P < 0.0001$].

Next, we analysed the impact of Peg-IFN α -2b on c-EVR in stratified analysis according to ribavirin dose. Figure 1 shows the relationship of c-EVR and the degree of Peg-IFN α -2b exposure for two groups of ribavirin doses: the group with ≥ 10.6 mg/kg/day of ribavirin and that with < 10.6 mg/kg/day (10.6 mg/kg/day was the median value). In either group, the mean dose of Peg-IFN α -2b was dose-dependently correlated with c-EVR ($P < 0.0001$), and c-EVR rates were very similar in both groups if the dose categories of Peg-IFN α -2b were the same.

Table 4 The c-EVR rate according to Peg-IFN and ribavirin doses during weeks 0–12 for patients who completed 12 weeks treatment

Ribavirin dose (mg/kg/day)**	Peg-IFN α -2b dose (μ g/kg/week),*				Total
	≥ 1.5	1.2–1.5	0.9–1.2	<0.9	
≥ 12	57% (60/105)	61% (22/36)	38% (6/16)	22% (2/9)	54% (90/166)
10–12	54% (46/85)	58% (154/267)	36% (14/39)	23% (11/47)	51% (225/438)
8–10	50% (25/50)	53% (52/99)	52% (15/29)	18% (4/22)	48% (96/200)
<8	46% (6/13)	44% (18/41)	24% (5/21)	21% (5/24)	34% (34/99)
Total	54% (137/253)	56% (246/443)	38% (40/105)	22% (22/102)	49% (445/903)

c-EVR, complete early virologic response; Peg-IFN, pegylated interferon.

* $P < 0.0001$ for comparison of the four Peg-IFN groups. ** $P = 0.05$ for comparison of the four ribavirin groups.




Fig. 1 Complete-EVR rate according to pegylated interferon alpha-2b (Peg-IFN α -2b) and ribavirin doses during weeks 0–12 for patients who completed 12 weeks of treatment. (— \blacktriangle) Group with the mean ribavirin dose <10.6 mg/kg/day. (--- \blacksquare) Group with the mean ribavirin dose ≥ 10.6 mg/kg/day. The Peg-IFN α -2b dose was dose-dependently correlated with c-EVR in both groups ($P < 0.0001$). There was no significant difference between the two ribavirin-dose groups ($P = 0.19$).

c-EVR rates according to Peg-IFN α -2b drug exposure using a percentage cut off and mean dose cut off

Table 5 shows the c-EVR rates according to the category of Peg-IFN α -2b doses during the first 12 weeks based on the

Table 5 The c-EVR rate according to Peg-IFN dose during weeks 0–12 based on the percentage of the planned dose and the mean doses

Peg-IFN α -2b dose (μ g/kg/week)	$\geq 80\%$	60–80%	<60%	Total
≥ 1.2	55%* (371/679)	71%** (12/17)	–	55% (383/696)
<1.2	32% (6/19)	38% (35/92)	22% (21/96)	30% (62/207)
Total	54% (377/698)	43% (47/109)	21% (21/96)	49% (445/903)

c-EVR, complete early virologic response; Peg-IFN, pegylated interferon.

* $P < 0.05$; patients with ≥ 1.2 μ g/kg/week vs <1.2 μ g/kg/week among the patients with more than 80% of the total prescribed dose of Peg-IFN α -2b. ** $P = 0.01$; patients with ≥ 1.2 μ g/kg/week vs <1.2 μ g/kg/week among the patients with more than 60–80% of the total prescribed dose of Peg-IFN α -2b.

percentage of the total prescribed dose and the mean doses. The whole c-EVR rate was 54% (377/698) for patients who received more than 80% of the prescribed dose, and 43% (47/109) in patients given 60–80% of the prescribed dose, and 21% (21/96) in patients given <60% of the prescribed dose of Peg-IFN α -2b. Among patients given $\geq 80\%$ of the prescribed dose of Peg-IFN α -2b, the c-EVR rate was significantly lower in patients given <1.2 μ g/kg/week of Peg-IFN α -2b than those given ≥ 1.2 μ g/kg/week (32% vs 55%, $P < 0.05$). On the other hand, even in patients given 60–80% of the prescribed dose of Peg-IFN α -2b, if they were given ≥ 1.2 μ g/kg/week of Peg-IFN α -2b, a higher c-EVR rate was attained in comparison with those given <1.2 μ g/kg/week (71% vs 38%, $P = 0.01$); the c-EVR rate in patients given 60–80% of the prescribed dose and ≥ 1.2 μ g/kg/week of Peg-IFN α -2b was not inferior to that in patients given $\geq 80\%$ of the prescribed dose and ≥ 1.2 μ g/kg/week of Peg-IFN α -2b.

Impact of dose exposure of Peg-IFN α -2b during the first 12 weeks of the treatment on HCV RNA negativity at week 24 and SVR

Patients positive for HCV RNA at week 24 week during Peg-IFN α -2b and ribavirin treatment were regarded as non-responders and stopped treatment [11]. We analysed the

relationship between the dose exposure to Peg-IFN α -2b during the first 12 weeks and HCV RNA negative rates at week 24 or SVR in 903 patients completing 12 weeks of treatment. As a result, HCV RNA negative rates at week 24 and SVR rates declined according to the decrease in the dose of Peg-IFN α -2b during the 12 weeks of treatment; patients given ≥ 1.5 , 1.2–1.5, 0.9–1.2 and < 0.9 $\mu\text{g}/\text{kg}/\text{week}$ of Peg-IFN α -2b during the first 12 weeks of the treatment showed HCV RNA negativity of 63%, 66%, 48% and 39%, respectively ($P < 0.0001$), and SVR of 46%, 43%, 30% and 20%, respectively ($P < 0.0001$).

DISCUSSION

Adherence to ribavirin was reported to be the important factor for EVR as well as that to Peg-IFN in most previous studies [2,11,12]. However, the drug exposure of Peg-IFN α -2b and ribavirin had not been analysed independently with respect to their individual influence on the anti-viral effect in these studies. Adherence to both drugs may be related factors, i.e. most patients who can tolerate a high dose of Peg-IFN are in good condition and thus can also receive a high dose of ribavirin. In the present study, the impact of the dose of Peg-IFN α -2b and ribavirin on the anti-viral effect was evaluated by multivariate logistic regression analysis, using the mean administration doses of both drugs during the first 12 weeks and baseline factors. As a result, the dose exposure of Peg-IFN α -2b was found to be the significant factor affecting c-EVR as well as baseline factors such as age, neutrophils and Plt values, but not ribavirin. This suggests that the c-EVR rate can be raised by maintaining the dose of Peg-IFN α -2b during the first 12 weeks in patients with disadvantageous factors at baseline. In fact, the c-EVR rate was higher in those who received ≥ 1.2 $\mu\text{g}/\text{kg}$ of Peg-IFN α -2b than in those given < 1.2 $\mu\text{g}/\text{kg}$ of Peg-IFN α -2b for aged patients over 60 years of age (≥ 1.2 $\mu\text{g}/\text{kg}$; 46% vs < 1.2 $\mu\text{g}/\text{kg}$; 28%, $P < 0.01$) or for patients with a low Plt value ($< 12 \times 10^4/\text{mm}^3$) (≥ 1.2 $\mu\text{g}/\text{kg}$; 45% vs < 1.2 $\mu\text{g}/\text{kg}$; 22%, $P < 0.001$). Therefore, a marked dose reduction of Peg-IFN α -2b should not be risked at the start even for aged patients or patients with lower Plt value, which is indicative of advanced fibrosis. The administration of ≥ 1.2 $\mu\text{g}/\text{kg}/\text{week}$ of Peg-IFN α -2b is desirable as a starting dose for achieving c-EVR even in these patients: that of < 1.2 $\mu\text{g}/\text{kg}/\text{week}$ can lead to a non-viral response or a late viral response. Independent evaluation of the c-EVR rate according to the degree of the ribavirin dose showed a stepwise decline as the total cumulative dose of Peg-IFN α -2b decreased. Therefore, the dose of Peg-IFN α -2b should be maintained as high as possible even in patients who have to reduce Peg-IFN α -2b to < 1.2 $\mu\text{g}/\text{kg}/\text{week}$. Using G-CSF for patients who develop severe neutropenia and are forced to decrease Peg-IFN can be beneficial, especially in the first 12 weeks.

The goal of 80% of the planned drug dosage for 80% of the assigned duration was derived from an adherence criterion

that had been adopted previously for assessment of the efficacy of other pharmaceutical agents, such as drugs to treat cancer and human immunodeficiency virus [16]. However, in Peg-IFN plus ribavirin therapy for patients with CH-C, the planned administration dose [17,18] differs on a body weight basis by 27% for Peg-IFN α -2b and 40% for ribavirin among patients of 50–100 kg of body weight, which would be equivalent to the same rate differences for 80% of the planned drug dosage. In detail, the target dose of Peg-IFN α -2b scheduled to be administered is 1.5 $\mu\text{g}/\text{kg}$, but the usual dose for the individual patient is from 1.28 to 1.76 $\mu\text{g}/\text{kg}/\text{week}$ based on body weight among patients weighing 50–100 kg according to the practice guidelines of the American Association for the Study of Liver Diseases and the manufacturer's drug information in the USA and Europe [17,18]. The range of ribavirin dose per kg of body weight is from 12 to 20 mg/kg/day. Therefore, in this study, the drug exposure was assessed from the average dose per kg of body weight.

In the evaluation of c-EVR rates according to Peg-IFN α -2b drug exposure using a percentage cut off and mean dose cut off in this study, the c-EVR rate of patients given < 1.2 $\mu\text{g}/\text{kg}/\text{week}$ of Peg-IFN α -2b was low (32%) even in those who received $\geq 80\%$ of the total planned doses of Peg-IFN α -2b. If given ≥ 1.2 $\mu\text{g}/\text{kg}/\text{week}$ of Peg-IFN α -2b, the c-EVR rate (71%) in patients who received 60–80% of the total doses was not inferior to that in patients given $\geq 80\%$ of the total dose of Peg-IFN α -2b (54%). This means that patients whose starting dose of Peg-IFN α -2b is < 1.5 $\mu\text{g}/\text{kg}/\text{week}$ should not have their dosage reduced to 80% of the planned dose (< 1.2 $\mu\text{g}/\text{kg}/\text{week}$) in order to have a higher probability of c-EVR, while those given ≥ 1.5 $\mu\text{g}/\text{kg}/\text{week}$ of Peg-IFN α -2b at the start can have their dosage reduced to 80% (≥ 1.2 $\mu\text{g}/\text{kg}/\text{week}$) without lowering the c-EVR rate. Thus, the drug dose on a body weight basis itself should be examined as an index of the drug exposure in order to evaluate the anti-viral effect of both drugs accurately for patients with CH-C.

As for the impact of the drug exposure to ribavirin on c-EVR, the drug dose of ribavirin during the first 12 weeks was shown to have no relationship with the c-EVR rate, although it was precisely evaluated in this study, using doses actually taken on body weight. However, ribavirin can be more effective for decreasing the viral relapse after interferon or Peg-IFN α -2b and ribavirin combination therapy in patients with CH-C genotype 1 [2,3,19–24]. Recently, Shiffman *et al.* [15] have reported that a higher starting dose of ribavirin (1000–1600 mg/day) plus a regular dose of Peg-IFN α -2b with epoetin was associated with a lower relapse rate in treatment with CH-C genotype 1. Considering the viral relapse after treatment, it is thought that the ribavirin dose should not be reduced quickly in patients with mild side effects, even though it does not affect c-EVR. In fact, among the patients who attained c-EVR, a higher rate of viral relapse was found in the patients given < 10 mg/kg/day of the mean ribavirin dose during 48 weeks in comparison

with those given ≥ 10 mg/kg/day of the mean ribavirin dose in this study [26.9% (49/182) vs 12.4% (26/209), $P < 0.001$] (data not shown). It seems possible to start ribavirin at a lower dose and increase it by degrees with monitoring of Hb level during treatment of patients with mild anaemia or ischemic heart disease, because the ribavirin dose appears to affect the viral relapse as the total dose over 48 weeks, not during the first 12 weeks.

In conclusion, our results have demonstrated that Peg-IFN α -2b is dose-dependently correlated with c-EVR and maintaining as high a drug dose of Peg-IFN α -2b as possible (≥ 1.2 $\mu\text{g}/\text{kg}/\text{week}$) during the first 12 weeks can yield higher c-EVR rates, leading to better treatment outcomes for patients with CH-C genotype 1.

ACKNOWLEDGMENTS AND DISCLOSURES

Other institutions and participants in the Osaka Liver Forum are: K Katayama, Osaka Koseinenkin Hospital; H Fukui, Yao Municipal Hospital; Y Doi, Otemae Hospital; A Kaneko, NTT West Osaka Hospital; T Kashihara, Itami City Hospital; K Kiriya, Ashiya Municipal Hospital; T Nagase, Suita Municipal Hospital; M Inada, Toyonaka Municipal Hospital; K Fujimoto, National Hospital Organization Minami Wakayama Medical Center; K Suzuki, Saiseikai Senri Hospital; H Ogawa, Nishinomiya Municipal Central Hospital; S Kubota, Kano General Hospital; M Nishiuchi, Saso Hospital; and N Imaizumi, Osaka Kaisei Hospital.

This work was supported by a Grant-in-Aid for Research on Hepatitis and BSE from Ministry of Health Labour and Welfare of Japan, and Scientific Research from the Ministry of Education, Science, and Culture of Japan.

REFERENCES

- Hayashi N, Takehara T. Antiviral therapy for chronic hepatitis C: past, present, and future. *J Gastroenterol* 2006; 41: 17–27.
- Manns MP, McHutchison JG, Gordon SC *et al*. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001; 358: 958–965.
- Fried MW, Shiffman ML, Reddy KR *et al*. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002; 347: 975–982.
- Hadziyannis SJ, Sette H Jr, Morgan TR *et al*. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med* 2004; 140: 346–355.
- Zeuzem S, Hultcrantz R, Bourliere M *et al*. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. *J Hepatol* 2004; 40: 993–999.
- Hiramatsu N, Hayashi N, Kasahara A *et al*. Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha. *J Hepatol* 1995; 22: 135–142.
- Kasahara A, Hayashi N, Mochizuki K *et al*. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. *Hepatology* 1998; 27: 1394–1402.
- Ikeda K, Saitoh S, Arase Y *et al*. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. *Hepatology* 1999; 29: 1124–1130.
- Kasahara A, Tanaka H, Okanoue T *et al*. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. *J Viral Hepatitis* 2004; 11: 148–156.
- Imai Y, Kasahara A, Tanaka H *et al*. Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response. *J Gastroenterol* 2004; 39: 1069–1077.
- Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. *Hepatology* 2003; 38: 645–652.
- McHutchison JG, Manns M, Patel K *et al*. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. *Gastroenterology* 2002; 123: 1061–1069.
- Shiffman ML, Ghany MG, Morgan TR *et al*. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. *Gastroenterology* 2007; 132: 103–112.
- Reddy KR, Shiffman ML, Morgan TR *et al*. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. *Clin Gastroenterol Hepatol* 2007; 5: 124–129.
- Shiffman ML, Salvatore J, Hubbard S *et al*. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. *Hepatology* 2007; 46: 371–379.
- Paterson DL, Swindells S, Mohr J *et al*. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. *Ann Intern Med* 2000; 133: 21–30.
- Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. *Hepatology* 2004; 39: 1147–1171.
- Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. *Gastroenterology* 2006; 130: 225–230.
- Poynard T, Marcellin P, Lee SS *et al*. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). *Lancet* 1998; 352: 1426–1432.
- McHutchison JG, Gordon SC, Schiff ER *et al*. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. *N Engl J Med* 1998; 339: 1485–1492.
- Davis GL, Esteban-MurR, Rustgi V *et al*. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. *N Engl J Med* 1998; 339: 1493–1499.

- 22 Hiramatsu N, Kasahara A, Nakanishi F *et al.* The significance of interferon and ribavirin combination therapy followed by interferon monotherapy for patients with chronic hepatitis C in Japan. *Hepatol Res* 2004; 29: 142–147.
- 23 Bronowicki JP, Ouzan D, Asselah T *et al.* Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. *Gastroenterology* 2006; 131: 1040–1048.
- 24 Hiramatsu N, Oze T, Yakushijin T, *et al.* Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2b plus ribavirin. *J Viral Hepat* 2009; In press.